Exosomes are small extracellular vesicles present in various body fluids such as saliva, urine, blood, and breast milk. These vesicles play an important role in intercellular communication processes and have specific composition of proteins, lipids, messenger RNA (mRNA), and micro RNA. Currently, exosomes have great potential to be used as a vehicle for drug delivery and a biomarker for the diagnosis of various diseases and for therapeutic use. Moreover, exosomes offer an alternative pathway for invasive biopsy used in the diagnosis and management of different types of cancer.
The global exosome diagnostic and therapeutic market is expected to reach $367 million by 2022, growing at a CAGR of 37.8% from 2016 to 2022. Increase in prevalence of cancer, growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global exosome diagnostic and therapeutic market. Moreover, technological advancements in exosomes isolation, analytical procedures, and innovative and advanced applications of exosomes also supports to the growth of the market. Stringent government regulations for the approval of exosomes diagnostic and therapeutic products and low awareness about the applications of exosomes hamper the market growth.
The world exosomes diagnostic and therapeutic market is segmented based on application, product, end user, and geography. Based on the application, it is divided into diagnostic and therapeutic applications. Based on the product, it is classified into instrument, reagents, and software used in the isolation and analysis of exosomes from cells and tissues. Based on end user, the market is segmented into cancer institute, institutes, hospitals, diagnostic centers, and others (medical universities, and not-for-profit organizations). Geographically, the market is segmented across four major regions, such as North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, and rest of Europe), Asia-Pacific (China, Japan, and rest of Asia-Pacific) and LAMEA.
Key benefits
The study provides an in-depth analysis of the exosome diagnostic and therapeutic market, with current trends and future estimations to elucidate the imminent investment pockets.
The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive market analysis by product assist in the treatment of various chronic and infectious diseases such as cancer, cardiovascular diseases, and other diseases.
Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
Key market players are profiled and their strategies are analyzed thoroughly, which predicts the competitive outlook of the market.
Key market segments
The world exosome diagnostic and therapeutic market is segmented into application, product, end user, and geography.
MARKET BY APPLICATION
Diagnostic
Therapeutic
MARKET BY PRODUCT
Instrument
Reagent
Software
MARKET BY END USER
Cancer Institute
Hospital
Diagnostic Center
Others
MARKET BY GEOGRAPHY
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Rest of Europe
Asia-Pacific
Japan
China
Rest of Asia-Pacific
LAMEA
KEY PLAYERS
Aethlon Medical, Inc.
Exosome Diagnostics Inc.
NanoSomix Inc.
Thermo Fisher Scientific Inc.
Malvern Instruments Ltd.
System Biosciences Inc.
NX Pharmagen
Sistemic Inc.
Capricor Therapeutics
Exiqon A/S
Other players in the value chain include (profiles not included in the report)
101BIO
AMS Biotechnology Limited
Therapeutic Solutions International, Inc.
ReNeuron Group plc
Immune Therapy Holdings AB
ExoCyte Therapeutics Pte Ltd
Cell Guidance Systems LLC
BioRegenerative Sciences, Inc.
Evomic Science LLC
Norgen Biotek Corp.
